37
Participants
Start Date
May 7, 2018
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
ribociclib
400mg PO
ribociclib
600mg PO
Bicalutamide
150mg PO
RECRUITING
University of Rochester Medical Center, Rochester
COMPLETED
Penn State Cancer Institute, Hershey
COMPLETED
Michigan State University, Lansing
RECRUITING
University of Wisconsin, Madison
RECRUITING
University of Illinois Cancer Center, Chicago
COMPLETED
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Novartis
INDUSTRY
Big Ten Cancer Research Consortium
OTHER
University of Wisconsin, Madison
OTHER
Kari Wisinski
OTHER